Current Updates on Asthma in Personalized Medicine
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".
Deadline for manuscript submissions: 25 June 2025 | Viewed by 2651
Special Issue Editor
Interests: asthma; COPD; small airway disease; mechanical ventilation; point-of-care ultrasonography; medical education
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The global burden of asthma continues to rise, with an estimated 300 million patients worldwide. Scientific evidence indicates that asthma is a heterogenous disorder characterized by chronic airway inflammation that varies over time in symptoms, intensity, and expiratory airflow limitation. Over the last two decades, research has focused on identifying the underlying molecular mechanisms underlying this heterogenity with the goal of personalizing treatment strategies. Despite recent advances in targeted therapies, CDC statistics show that up to 60% of adults with current asthma can be uncontrolled. This Special Issue aims to advance knowledge on clinical and translational advances in asthma, with a focus on identifying endotypes, phenotypes, and treatable traits; novel treatment approaches, including inhalational strategies; targeted therapies; and ethnic and racial differences in response to treatment and treatment challenges. We are soliciting clinical studies, review articles, systematic reviews, and meta-analyses for this Special Issue.
Dr. Muhammad Adrish
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- asthma
- treatable traits
- biomarkers
- novel inhalational strategies
- targeted therapies
- non-pharmacological management
- machine learning approaches
- racial/ethnic differences in response to therapies
- treatment challenges
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
